|
Who benefits from allogeneic transplantation for myelodysplastic syndromes?: new insights
|
Dec 2013
|
Hematology Am Soc Hematol Educ Program
|
myelodysplastic syndromes (MDS)
|
|
Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It?
|
Jun 2015
|
Clin Lymphoma Myeloma Leuk
|
myelodysplastic syndromes (MDS)
|
|
Where There's Smoke, There's Fire: Inflammation Drives MDS
|
Jul 2020
|
Trends in immunology
|
myelodysplastic syndromes (MDS)
|
|
When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
|
Dec 2013
|
Best Pract Res Clin Haematol
|
myelodysplastic syndromes (MDS)
|
|
What causes aplastic anaemia?
|
Apr 2023
|
Leukemia
|
aplastic anemia
|
|
VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases
|
Apr 2023
|
Internal and Emergency Medicine
|
myelodysplastic syndromes (MDS)
|
|
Very Severe Aplastic Anemia During Treatment With Doxycycline
|
Oct 2016
|
Am J Ther.
|
aplastic anemia
|
|
Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure
|
Jul 2020
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience
|
Nov 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response
|
Mar 2015
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
